Hospital Admissions for Drug-Induced Liver Injury: Clinical Features, Therapy, and Outcomes

Cell Biochemistry and Biophysics

Volumn 64, Issue 2, 2012, Pages 77-83

  Hou, Feng Qin ^a   Zeng, Zheng ^a   Wang, Gui Qiang ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Drugs; Liver injury; Steroid therapy

Indexed keywords

ALKALINE PHOSPHATASE; ANTIINFECTIVE AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARDIOVASCULAR AGENT; PLANT MEDICINAL PRODUCT; STEROID;

ADOLESCENT; ADULT; AGED; DISEASE COURSE; DRUG EFFECT; ENZYMOLOGY; FEMALE; HOSPITALIZATION; HUMAN; LIVER; LIVER TRANSPLANTATION; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; REVIEW; STATISTICS; TOXIC HEPATITIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANTI-BACTERIAL AGENTS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CARDIOVASCULAR AGENTS; DISEASE PROGRESSION; DRUG-INDUCED LIVER INJURY; FEMALE; HOSPITALIZATION; HUMANS; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PLANT PREPARATIONS; RETROSPECTIVE STUDIES; STEROIDS; TREATMENT OUTCOME;

EID: 84867744027     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-012-9373-y     Document Type: Review

References (30)

1. Takikawa, H. (2009). Recent status of drug-induced liver injury. Hepatology Research, 39, 1-6.
2. Norris, W., Angelo, H., & Paredes, A. H. (2008). Drug-induced liver injury in 2007. Current Opinion n Gastroenterology, 24, 287-297.
3. Kaplowitz, N. (1996). Drug metabolism and hepatotoxicity. In N. Kaplowitz (Ed.), Liver and biliary diseases (2nd ed., pp. 103-120). Baltimore, MD: Williams and Wilkins.
4. Zimmerman, H. (1999). Drug-induced liver disease. In E. Schiff, M. Sorrell, & W. Madrey (Eds.), Schiff's diseases of the liver (8th ed., pp. 973-1064). Philadelphia, PA: Lippincott-Raven.
5. Ostapowicz, G, Fontana, R. J., Schiodt, F. V., et al. US Acute Liver Failure Study Group. (2002). Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Annals of Internal Medicine, 137, 947-954.
6. Lee, W. M. (2003). Drug-induced hepatotoxicity. The New England Journal of Medicine, 349, 474-485.
7. Bjorneboe, M., Iversen, O., & Olsen, S. (1967). Infective hepatitis and toxic jaundice in a municipal hospital during a five year period: Incidence and prognosis. Acta Medica Scandinavica, 182, 491-501.
8. Malchow-Moller, A., Matzen, P., Bjerregaard, B., Hilden, J., Holst-Christensen, J., & Staehr, J. T. (1981). Causes and characteristics of 500 consecutive causes of jaundice. Scandinavian Journal of Gastroenterology, 16, 1-6.
9. Whitehead, M. W., Hainsworth, I., & Kingham, J. G. C. (2001). The causes of obvious jaundice in South West Wales: 2000. Gut, 48, 409-413.
10. Björnsson, E., Ismael, S., Nejdet, S., & Kilander, A. (2003). Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis. Scandinavian Journal of Gastroenterology, 38, 86-94.
11. Vuppalanchi, R., Liangpunsakul, S., & Chalasani, N. (2006). Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States. The American Journal of Gastroenterology, 101, 1-5.
12. Wei, G., Bergqvist, A., Broome, U., & Björnsson, E. (2004). Acute liver failure in Sweden: etiology and prognosis [abstract 48]. Scandinavian Journal of Gastroenterology, 39, 36.
13. Williams, R. (1996). Classification, etiology, and considerations of outcome in acute liver failure. Seminars in Liver Disease, 16, 343-348.
14. Hou, F.-Q., Wang, T.-L., Liu, X., Huo, N., & Wang, G.-Q. (2010). The clinical and histological characteristics and outcomes of drug induced chronic liver injury after removing causative drugs. Hepato-Gastroenterology, 57, 554-561.
15. Wei-ting, L., Jun, L., Ning, O., Chen, N., Liu, Y., & Guo, X. J. (2006). An analysis of 276 cases of drug induced liver damage. Chinese Journal of Hepatology, 14, 832-834.
16. Danan, G., & Benichou, C. (1993). Causality assessment of adverse reactions to drugs: A novel method based on the conclusions of international consensus meetings: Application to drug induced liver injuries. Journal of Clinical Epidemiology, 46, 1323-1330.
17. Benichou, C. (1990). Criteria of drug-induced liver disorders. Report of an international consensus meeting. Journal of Hepatology, 11, 272-276.
18. World Health Organisation Collaborating Centre for Drugs Statistics Methodology: Anatomical Therapeutic Chemical (ATC) Classification Index Including Defined Daily Dose (DDDs) for Plain Substances. Oslo: World Health Organization Collaborating Centre for Drugs Statistics Methodology, 2002.
19. Sgro, C., Clinard, F., Ouazir, K., Chanay, H., Allard, C., & Guilleminet, C. (2002). Incidence of drug induced hepatic injuries: A French population-based study. Hepatology, 36, 451-455.
20. Ibanez, L, Perez, E, Vidal, X, Laporte, J. R., Grup d'Estudi Multicenteric d'Hepatotoxicitat Aguda de Barcelona (GEMHAB). (2002). Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. Journal of Hepatology, 37, 592-600.
21. Ahmad, S. R. (2003). Adverse drug event monitoring at the Food and Drug Administration. Your report can make a difference. Journal of General Internal Medicine, 18, 57-60.
22. Russo, M. W., Galanko, J. A., Shrestha, R., Fried, M. W., & Watkins, P. (2004). Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transplantation, 10, 1018-1023.
23. Andrade, R. J., Lucena, M. I., Fernandez, M. C., Pelaez, G., Pachkoria, K., & García-Ruiz, E. (2005). Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology, 129, 512-521.
24. Friis, H., & Andreasen, P. B. (1992). Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish committee on adverse drug reactions between 1978 and 1987. Journal of Internal Medicine, 232, 133-138.
25. Smith, I. D. M., Simpson, K. J., Garden, O. J., Larson, A., Davern, T. J., & Han, S. H., the U. S. Acute Liver Failure Study Group. (2002). Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Annals of Internal Medicine, 137, 947-954.
26. Bjornsson, E., & Olsson, R. (2005). Outcome and prognostic markers in severe drug-induced liver disease. Hepatology, 42, 481-489.
27. Bjornsson, E., Jerlstad, P., Bergqvist, A., & Olsson, R. (2005). Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scandinavian Journal of Gastroenterology, 40, 1095-1101.
28. Andrade, R. J., Lucena, M. I., Kaplowitz, N., García-Muņoz, B., Borraz, Y., & Pachkoria, K. (2006). Outcome of acute idiosyncratic drug induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology, 44, 1581-1588.
29. Björnsson, E., Kalaitzakis, E., Av Klinteberg, V., Alem, N., & Olsson, R. (2007). Long-term follow-up of patients with mild to moderate drug induced liver injury. Alimentary Pharmacology & Therapeutics, 26, 79-85.
30. Ohmori, S., Shiraki, K., Inoue, H., Yamanaka, T., Deguchi, M., & Sakai, T. (2003). Clinical characteristics and prognostic indicators of drug-induced fulminant hepatic failure. Hepato-Gastroenterology, 50, 1531-1534.